The healthcare market is poised to see some of the earliest benefits of nanotechnology. Over the next decade, it will be one of nanotech highest growth sectors. Targeted drug delivery therapies for the treatment of cancer is one of the most commonly cited nano-healthcare benefits. Nanotechnology in Drug Delivery Market Report, gives a comprehensive analysis and geographic breakdown of the current nanotechnology drug delivery market and its most relevant technologies. It also provides a forecast for the size of total addressable markets and percent share of those key technologies.
Some forecasts have predicted the nanotechnology market to reach close to a trillion dollars by 2015, presenting investors with unique opportunities. However, the market for applications of nanotechnology is complex, multidisciplinary and highly segmented. It is therefore essential to gain an understanding of which market sectors nanotechnology is likely to impact most profoundly in the near term.
Since we now know most (if not all) biological processes occur at the nanoscale, the application of life science principles – studying the causes of biological phenomena at the molecular level – means medical and biomedical research is increasingly using a bottom-up (rather than the top-down) approach. The low bioavailability resulting from traditional oral and intravenous drug delivery methods and the market forces at work in the pharmaceutical industry, where patents expire after a relatively short period of time unless a novel form of drug delivery is developed that will extend the patent, are two major forces that will fuel the growth of the nanotech drug delivery market. The third factor at play is a combination of improved global health and a correspondingly dramatic increase in the size of the global aging population.
Both sets of data are segmented into market by geographical region (US$ millions, % share, and compound annual growth rates by country) for America; Asia, Europe, and Rest of the World (key economies only) and by technology type (US$ millions, percent share and compound annual growth rate). Technology types examined include:
- Solubility & Bioavailability
- Targeted Delivery
- Drug Nanocrystals
- Total Nanocarriers
- Carbon nanotubes
- Gold Nanocarriers
- Polymer-based Nanocarriers
- Ceramic Nanocarriers
- Calcium phosphate Nanocarriers
Also included in the report is:
- An overview of nanotechnology;
- Identification of several key drivers for nanotechnology adoption in medicine and biomedicine;
- The most important fields for the adoption of nanotechnology in medicine; and
- An explanation of how nanotechnology is already having an impact on the drugs delivery sector through several relevant case studies.
In addition to an examination of general trends, Nanotechnology in Drug Delivery identifies five current & future challenges to as well as the major barriers to adoption of nanotechnology in medicine and biomedicine and provides a Technology Adoption Roadmap.
The report examines the stage of development of key nanotechnologies used in drug delivery, sorted by applications, including
- Nanobiotechnology in drug delivery
- Analytical techniques for nanoparticle drug delivery
- Clinically approved nanocarrier-based formulations present on the market and in the pipeline
- Clinically approved nanocrystals-based formulations present on the market and in development
- Nanotechnology-based alternatives to nanocarriers in drug delivery
- Present and future applications
New report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. The report profiles 60 companies including many key and niche players such as –
Access Pharmaceuticals, Inc.
Capsulution Pharma AG